BioPharmSignal logoBioPharmSignal

Company Profile

Satsuma Stock Price, News & Analysis

Ticker:
STSA
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Why the stock is moving

Current closing-price context is not available for STSA.

Company overview

Business overview

Satsuma Pharmaceuticals was a migraine and CNS company focused on acute treatment delivery before its acquisition and restructuring. Its story centered on using inhaled delivery for migraine therapy.

Geographic Base and Sector Classification

Headquartered in the United States and listed on NASDAQ before acquisition, Satsuma sat in specialty biotechnology.

Business Model Characteristics

The company depended on clinical validation, delivery technology, and the commercial opportunity in migraine care.

Position Within the Biotechnology Landscape

Satsuma is best treated as a historical CNS and specialty-pharma case rather than a live catalyst name.

Future catalysts

Satsuma’s catalyst set is now mostly legacy and transition-related, with any remaining update focused on how the migraine asset base is being handled. The market is no longer treating it like a fresh standalone growth story.

Recent news

  1. 01

    Satsuma Pharmaceuticals Announces Presentation of Two Clinical Program Abstracts at the American Headache Society's 68th Annual Scientific Meeting

    Source: Satsuma

  2. 02

    Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache

    Source: Satsuma

  3. 03

    Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific Meeting

    Source: Satsuma

  4. 04

    Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine

    Source: Satsuma

  5. 05

    Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura

    Source: Satsuma

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

CING

Cingulate Inc.

ATAI

ATAI Life Sciences

VAXX

Vaxxinity

DRRX

DURECT Corporation

BLPH

Bellerophon Therapeutics

MNKD

MannKind

MTP

Midatech Pharma

DNCE

Aerami

Frequently Asked Questions

What does Satsuma do?

Satsuma Pharmaceuticals was a migraine and CNS company focused on acute treatment delivery before its acquisition and restructuring. Its story centered on using inhaled delivery for migraine therapy.

On which exchange is STSA stock listed?

Satsuma (STSA) is associated with NASDAQ, United States, Biopharma.

What is Satsuma?

Satsuma’s catalyst set is now mostly legacy and transition-related, with any remaining update focused on how the migraine asset base is being handled.

Which conditions is Satsuma targeting with Satsuma?

Satsuma’s catalyst set is now mostly legacy and transition-related, with any remaining update focused on how the migraine asset base is being handled.

How does Satsuma describe recent progress with Satsuma?

Satsuma’s catalyst set is now mostly legacy and transition-related, with any remaining update focused on how the migraine asset base is being handled.

What is Pharmaceuticals?

Satsuma Pharmaceuticals was a migraine and CNS company focused on acute treatment delivery before its acquisition and restructuring.

What should investors watch for with Pharmaceuticals?

Satsuma’s catalyst set is now mostly legacy and transition-related, with any remaining update focused on how the migraine asset base is being handled. The market is no longer treating it like a fresh standalone growth story.

What future catalysts are investors watching for Satsuma?

Satsuma’s catalyst set is now mostly legacy and transition-related, with any remaining update focused on how the migraine asset base is being handled. The market is no longer treating it like a fresh standalone growth story.